Jak2 FERM Domain Interaction with the Erythropoietin Receptor Regulates Jak2 Kinase Activity
暂无分享,去创建一个
[1] Xinming Cai,et al. Structural Basis for the Autoinhibition of Focal Adhesion Kinase , 2007, Cell.
[2] J. Ihle,et al. Jak2: normal function and role in hematopoietic disorders. , 2007, Current opinion in genetics & development.
[3] T. Matsuda,et al. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2 , 2006, The EMBO journal.
[4] J. Ihle,et al. Two Domains of the Erythropoietin Receptor Are Sufficient for Jak2 Binding/Activation and Function , 2006, Molecular and Cellular Biology.
[5] O. Silvennoinen,et al. Binding of SH2-B Family Members within a Potential Negative Regulatory Region Maintains JAK2 in an Active State , 2006, Molecular and Cellular Biology.
[6] M. G. Myers,et al. Phosphorylation of Jak2 on Ser523 Inhibits Jak2-Dependent Leptin Receptor Signaling , 2006, Molecular and Cellular Biology.
[7] A. Stensballe,et al. Phosphorylation of JAK2 at Serine 523: a Negative Regulator of JAK2 That Is Stimulated by GrowthHormone and Epidermal Growth Factor , 2006, Molecular and Cellular Biology.
[8] M. G. Myers,et al. Phosphorylation of Jak2 on Ser523 InhibitsJak2-Dependent Leptin ReceptorSignaling , 2006, Molecular and Cellular Biology.
[9] H. Lodish,et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[10] Stefan N. Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.
[11] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[12] M. Tremblay,et al. Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. , 2005, Current opinion in cell biology.
[13] D. Barber,et al. Turning cells red: signal transduction mediated by erythropoietin. , 2005, Trends in cell biology.
[14] Y. Sekine,et al. Determination of the transphosphorylation sites of Jak2 kinase. , 2004, Biochemical and biophysical research communications.
[15] H. Steen,et al. Autophosphorylation of JAK2 on Tyrosines 221 and 570 Regulates Its Activity , 2004, Molecular and Cellular Biology.
[16] M. G. Myers,et al. Tyrosine Phosphorylation of Jak2 in the JH2 Domain Inhibits Cytokine Signaling , 2004, Molecular and Cellular Biology.
[17] J. O’Shea,et al. Tyrosine 813 Is a Site of JAK2 Autophosphorylation Critical for Activation of JAK2 by SH2-Bβ , 2004, Molecular and Cellular Biology.
[18] Mauno Vihinen,et al. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. , 2003, Molecular biology of the cell.
[19] Fabrizio Giordanetto,et al. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. , 2002, Protein engineering.
[20] D. Barford,et al. TYK2 and JAK2 Are Substrates of Protein-tyrosine Phosphatase 1B* , 2001, The Journal of Biological Chemistry.
[21] J. Roberts,et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. , 2001, Molecular cell.
[22] J. Ihle,et al. The distal region and receptor tyrosines of the Epo receptor are non‐essential for in vivo erythropoiesis , 2001, The EMBO journal.
[23] Josef M. Penninger,et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling , 2001, Nature.
[24] A. Yoshimura,et al. The JAK‐binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop , 1999, The EMBO journal.
[25] J. Marine,et al. Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.
[26] A. Cumano,et al. Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis , 1998, Cell.
[27] R Berger,et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.
[28] T. Taniguchi,et al. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[29] I. Kerr,et al. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop , 1997, Molecular and cellular biology.
[30] S. Pestka,et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses , 1997, Molecular and cellular biology.
[31] J. Ihle,et al. Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response , 1996, Molecular and cellular biology.
[32] I. Sakai,et al. Regions of the JAK2 Tyrosine Kinase Required for Coupling to the Growth Hormone Receptor (*) , 1995, The Journal of Biological Chemistry.
[33] A. Kraft,et al. The Amino-terminal Portion of the JAK2 Protein Kinase Is Necessary For Binding and Phosphorylation of the Granulocyte-Macrophage Colony-stimulating Factor Receptor β Chain (*) , 1995, The Journal of Biological Chemistry.
[34] N. Perrimon,et al. Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. , 1995, The EMBO journal.
[35] H. Luo,et al. An amino acid substitution in the Drosophila hopTum‐l Jak kinase causes leukemia‐like hematopoietic defects. , 1995, The EMBO journal.
[36] Ursula Klingmüller,et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals , 1995, Cell.